Newsfeeds Archive - Spark Newswire

1 minute read

Pulmatrix Announces Peer-Reviewed Publication Headache: The Journal Of Head And Face Pain, Clinical Results For Its Orally Inhaled DHE For Acute Migraine

May 15, 9:31 AM

Orally Inhaled PUR3100 is associated with rapid systemic PK within the therapeutic window and a mean time to Cmax matching intravenously (IV) administered DHE.Self-administered PUR3100 showed improved safety and

PULM

22 minute read

Stocks That Hit 52-Week Lows On Wednesday

By Benzinga Insights

October 4, 12:01 PM

On Wednesday, 311 stocks hit new 52-week lows.

AADI

25 minute read

Options

Stocks That Hit 52-Week Lows On Tuesday

By Benzinga Insights

September 26, 12:04 PM

On Tuesday, 386 stocks made new 52-week lows.

$TKO

14 minute read

Options

Stocks That Hit 52-Week Lows On Friday

By Benzinga Insights

September 8, 1:58 PM

Friday's session saw 225 companies set new 52-week lows.

AAMC

4 minute read

Options

Stocks That Hit 52-Week Lows On Wednesday

By Benzinga Insights

August 30, 1:18 PM

On Wednesday, 59 companies achieved new lows for the year.

AKTS

7 minute read

Options

Stocks That Hit 52-Week Lows On Tuesday

By Benzinga Insights

August 29, 2:37 PM

On Tuesday, 99 stocks hit new 52-week lows.

AGIL

2 minute read

Pulmatrix Announces Submission Of IND Application To FDA To Initiate A Phase 2 Trial Of Investigational Drug PUR3100 To Treat Acute Migraine

By Happy Mohamed

July 11, 9:06 AM

Pulmatrix, Inc. ("Pulmatrix" or the "Company") (NASDAQ:PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and central nervous

PULM

8 minute read

Options

Stocks That Hit 52-Week Lows On Monday

By Benzinga Insights

May 15, 1:46 PM

On Monday, 120 stocks hit new 52-week lows.

ADTH

13 minute read

Options

Stocks That Hit 52-Week Lows On Thursday

By Benzinga Insights

April 27, 12:16 PM

On Thursday, 185 companies achieved new lows for the year.

ADMP

4 minute read

Pulmatrix Announces Year-End And Q4 Financial 2022 Results And Provides Corporate Update; $35.6M In Cash And Cash Equivalents At The End Of 2022 Providing Cash Runway Into Q2 2024

By Happy Mohamed

March 30, 9:07 AM

PUR1900 Phase 2b study dosed first patients in Q1 2023 PUR3100 Phase 1 study achieves positive topline results as announced in Q1 2023 $35.6 million in cash and cash equivalents at

PULM